Monthly Archives: November 2013

Subcommittee Hearing Sheds Light on Opioid Overdose Deaths among VA Patients

On October 10, 2013, the House Committee on Veterans’ Affairs’ Subcommittee on Health held a hearing on the topic of the “VA’s [Veteran Affairs] Skyrocketing Use of Prescription Painkillers to Treat Veterans.”  The committee called on doctors, military personnel, family, and government officials to learn more about the alarming increase of prescriptions to veterans by VA hospitals and its effect on patients.

The problem has been dramatically increasing since September 11, 2001, as a wave of new veterans returned home from the multiple theaters of the War on Terror.  The Center for Investigative Reporting has found that prescriptions of four drugs – hydrocodone, oxycodone, methadone, and morphine – have been prescribed 270% more over the past 12 years and contributed to a fatal overdose rate of double the national average among VA patients.  In addition, a study by the San Francisco VA Medical Center found that patients with PTSD and depression were more likely to receive higher-dose opioid prescriptions, 2 or more opioids concurrently, sedative hypnotics concurrently with other opioids, or obtain early opioid refills.  This is despite the fact that opioids can hinder recovery from PTSD and other mental health conditions.

One contributing factor is the sheer number of patients, therefore limiting the amount of doctor-patient time that would otherwise be afforded in VA hospitals.  Josh Renschler, Sergeant US Army (Ret.), spoke at the hearing about how his primary care VA appointments would sometimes be 3 months apart despite the pain from a mortar attack in 2008 being “wildly out of control.”  Between appointments, the only care he could receive was increased prescriptions, causing him to take up to 12 pills a day, some of which were prescribed simply to counteract the effects of others.  Another contributing factor to the increase in opiate prescriptions is veterans’ limited access to help outside the VA.  A submission to the hearing by the Iraq and Afghanistan Veterans of America (IAVA) noted that some barriers to treating chronic pain included “formulary barriers, inability to access state prescription monitoring programs (which would allow [medical personnel] to see if patients have previously been prescribed controlled medications like opioids), and barrier[s] to consulting with experts outside of the VA.”

In some cases, doctors do not want to prescribe opioids, but are forced to by the hospital administration.  One doctor at the subcommittee hearing, Dr. Pamela J. Gray, recounted that she was forced to prescribe opioids against her better judgment.  She was hired by the VA Medical Center in Hampton, Virginia where she was forced into a “pain specialist” role even though she had no prior specialized training.  She explained that she dealt with difficult pain patients with “large doses of Schedule II narcotics.” (Schedule II narcotics are those with medical benefits that otherwise have a high risk of abuse and dependency.)  When she attempted to move away from opioid prescriptions, she received pressure from service chiefs, nurses, the Chief of Medicine at the hospital, and even non-medical personnel such as patient care advocates and administrative assistants to keep her prescription rates steady.  Her continued efforts to reduce prescriptions and even to help patients seek mental health consultations eventually cost Dr. Gray her job.

The VA is aware of the problem and working towards a solution.  In 2009 it implemented VHA [Veteran’s Health Administration] Directive 2009-053 which, among other things, provided a plan to treat pain in VA patients. The plan included behavioral and mental health monitoring, physical rehabilitation, use of advanced diagnostic services, seeking of specialty consultations, and monitoring effectiveness of prescribed drugs to determine if they should continue to be used.  However, despite recognizing the severity of the problem and that more complex treatments are needed, prescriptions continued to rise.

Leave a Comment

Filed under Uncategorized

Patient Protection and Affordable Care Act: Smoking Surcharges Could Cost You

        After strong opposition from multiple states which culminated in the Supreme Court case National Federation of Independent Business v. Sebelius, health insurance exchanges of the Patient Protection and Affordable Care Act (PPACA) began implementation on October 1, 2013.  Though not without website glitches and continuing opposition from House and Senate Republicans, the White House has claimed that many people have signed up and have begun to take advantage of the benefits the PPACA has to offer. (White House)  To be clear, the PPACA is a federal law with state components, including specific state insurance exchanges.  Following the NFIB v. Sebelius, several states with legislatures controlled by Republicans opted to reject the expanded Medicaid coverage provided for by the Act.  As of September 2013, 25 states and the District of Columbia have adopted the Medicaid expansion.  (  States that have not yet expanded their Medicaid programs can choose to opt in at a later time.  (CNN Money)

            What has come to light since the PPACA has been implemented is the significant impact it will have for smokers.  (Journal Times)  While one of the purposes of the PPACA exchanges is to reduce the cost of insurance across the board, not enrolling without a penalty (or having an alternate source of health insurance) is currently not an option for smokers and non-smokers alike.

            In fact, smokers in some states may have to pay as much 50% more in premiums than non-smokers if they sign up for insurance through the PPACA. (USA Today)  In some cases, the premium that smokers will pay might completely negate the subsidy for which some smoking health plan enrollees would qualify for in the marketplace. (Chicago Sun Times)  For example, if someone would qualify for a $6,000 subsidy on an insurance policy costing $8,000, his out-of-pocket cost would be $2,000.  Under the PPACA, factoring in the 50% surcharge on the original $8,000 sticker price, the same plan might cost $12,000.  However, he would still only get a $6,000 subsidy, because the subsidy cannot be applied to the smokers’ penalty.  That means he would ultimately pay $6,000 out of pocket, instead of $2,000. (Reuters)

            Smokers tend to be overrepresented in the lower income demographic, who currently rank high among the uninsured.  Incidentally, those who fall in the relatively lower income bracket are the people who would be most likely to want to buy insurance through the PPACA because they are currently uninsured.  If the goal of the Affordable Care Act is to protect the most vulnerable by offering them affordable insurance, then it seems paradoxical to dissuade smokers — who make up a fifth or more of the population — from signing up.  (Reuters)

            Organizations such as the American Lung Association favor the 50% premium surcharge, as they see it potentially providing the impetus smokers need to quit their habit.  They have characterized the premium as providing a focus on prevention in healthcare, especially as related to tobacco cessation.  (  It seems as though the purpose of the higher premium charges are to penalize the people who put not only themselves but others at risk by smoking, and incentivize ceases such behvarior. (USA Today)

            Regardless of the purpose of the PPACA’s treatment of smokers, Washington, D.C. and states including California, Massachusetts, Rhode Island, Connecticut, New Jersey, New York and Vermont have already taken the steps to prohibit insurers from applying a tobacco surcharge.  Many other states have lowered the maximum surcharge allowed.  (Web MD)  How this premium will impact the popularity of the PPACA with the 20% of the population comprised of smokers is yet to be seen.

Leave a Comment

Filed under Uncategorized

Drug Shortages and Legislative Solutions

Cancer patients, and patients with a wide range of other ailments, may not be receiving the best possible medicine because the required drugs are in shortage.  The prescription drug market is consistently afflicted with shortages, both minor and major.  Each shortage can affect one particular drug, or a range of drugs within a class.  In 2011, the United States experienced 251 drug shortages. In the same year, 183 (nearly 75%) of these shortages were of sterile injectable drugs, most commonly used for cancer treatments.  (FDA Factsheet)  Doctors do not have the option to prescribe the drugs they believe to work best because they are unavailable.  (The New York Times)

Manufacturing costs are a major contributor to the problem.  Sterile injectable drugs are very costly to make, and thus not many companies are willing to take the risk of setting up facilities to make them.  Further, the facilities that make such medicines are subject to many regulatory rules, including caps on drug prices. This means that, even when there is strong market demand for more product, manufacturers may not be able to afford to produce them, Plainly said, these drugs do not become more expensive when supply is at issue, as they might in an unregulated market, they become scarce. The manufacturing web is so fragile that a certain factory closing can extend a shortage for several months or even years.  (Medscape)

The prescription drug market is “characterized by sporadic shortages of individual drugs and occasional periods during which many drugs in a class are in shortage,” and few legislative or regulatory solutions have made a difference in solving the problem.  (ASPE Brief)  The Food and Drug Administration (FDA) takes measures to prevent and solve these shortages, which include working closely with drug manufacturers to help restore availability and working with other potential manufacturers to encourage them  to increase production to prevent future shortages.  (  Unfortunately for FDA, its power is limited, and legislative response to this problem has been insufficient.

In 2012, Congress passed the Food and Drug Safety and Innovation Act of 2012 (FDASIA).  Title X of that Act is committed to the issue of drug shortages, and, in part, requires that manufacturers give the FDA prior notification when a shortage is predicted.  Other requirements laid out in Title X include allowances for expedited FDA review of drugs that may help alleviate a shortage, creating an FDA task force dedicated to the issue of shortages, maintaining a drug shortages list, agency analysis of manufacturing quotas (including the ability to change the quotas if a particular drug seems likely to be in shortage), and allowances for hospital repackaging of drugs so that they may be distributed in a more efficient way.  (FDASIA 2012 Summary)

Title X puts forth ideas that could potentially solve part or all of the shortages problem, but some of these measures have flaws that make them potentially useless.  FDASIA undercuts itself often.  For example, section 506D of Title X mandates the creation of a drug shortages taskforce.  The taskforce is to create a strategic plan which should include measures to increase communication between manufacturers and FDA.  The taskforce should also ensure that the Secretary of Health and Human Services considers shortages when executing regulatory actions, considers the implications shortages have on clinical trials, and examines opportunities for more manufacturing partnerships.  Given enough time, these steps could create a useful taskforce, especially if it fosters improved communications between manufacturers and the agency regulating them. But the taskforce is simply not given the time required to become fully ingrained in the market/regulation system.  Section 506(f) is a sunset provision, meaning that the structure and purpose of the taskforce are to end exactly five years after the bill was enacted.  This means that even if it begins to succeed, the taskforce will cease its operations at the end of five years.  It has, essentially, been hobbled with “lame duck” status since the very instant it was created.  Though sunset provisions are not uncommon in legislative acts, one as short as five years does not give the taskforce much time to assert itself before losing its mandate.  Generally, sunset provisions are meant to prevent outdated laws in the far future, but here the sunset provision renders the taskforce useless in a much smaller timeframe.

Despite the other contradictory measures, at least one part of the FDASIA has been proven effective: the early notice requirement.  This requirement forces manufacturers to inform FDA if they anticipate a shortage to be imminent, and has been effective in helping to coordinate efforts to curb existing shortages or even prevent them outright.  The effectiveness of the plan can be seen in the numbers: new shortages are at the lowest they have been since 2006.  (Salon)  It is possible that, given enough time, other sections of the act will prove equally or more effective, and in the future shortages will not be as much of a burden on the medical community as they currently are.  But unless new ideas and initiatives are given more time to become effective and do their jobs, drug shortages will remain a serious problem for the medical community.

Leave a Comment

Filed under Uncategorized